Research
Hormonal
Tirzepatide, a GLP-1/GIP receptor co-agonist, is approved for type 2 diabetes and shows significant reductions in glycemia and body weight compared to GLP-1R mono-agonism with semaglutide.
Tirzepatide may be a more effective treatment option for managing blood sugar and weight in patients with type 2 diabetes.
StrongSupportsmedium confidence
Phase 3 trials in T2D cohorts revealed significant reductions in glycemia and body weight and superiority compared with GLP-1R mono-agonism with semaglutide.
Why this rating
Based on phase 3 trial data.
Source
Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data
Ronald Goldenberg et al. · Current Opinion in Cardiology · 2023
DOI 10.1097/hco.0000000000001084
reviewCited 12×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →